Clinical Trials Browser

Margins of Excision × Interferon alpha-2 × Clear all

NCT00719264 2017-03-20

Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer

Phase 2 Completed

365 enrolled 14 charts

Margins of Excision, Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell